The News Review:

- £20m ploughed into research centres
- Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir …
- Myriad Genetics Inc. Expands Commercial and Clinical Infrastructure
- Healthcare Discoveries Inc. Central ECG Laboratory Services Partner…
- Weight-loss operation can send diabetics into remission

£20m ploughed into research centres
channel4.com – Jan 23, 2008
The centres – to be established at existing facilities in Newcastle Cardiff Cambridge Nottingham and Belfast – will receive up to £5 million each for research into key public health issues. The initiative is being funded by the UK Clinical Research Collaboration an umbrella group made up of health charities and regional bodies. Spread over a five-year period the money will go towards providing academic jobs and training opportunities as well as boosting equipment and IT systems. Professor Ian Diamond chief executive of the Economic and Social Research Council leading the funding group said: “I am delighted to announce these important new centres which will be vital for bringing together world class experts from a diverse range of backgrounds to ensure that essential research is carried out to make a significant impact on the public health of the UK population. The five newly established centres of excellence will research topics such as diet and nutrition alcohol physical activity tobacco and drugs. The UK Clinical Research Collaboration consists of the British Heart Foundation Cancer Research UK the Economic and Social Research Council the Health and Social Care Research and Development ffice for Northern Ireland the Medical Research Council the National Institute for Health Research the Wales ffice of Research and Development and the Wellcome Trust.

Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir …
Free with registration – Business Wire – AccessMyLibrary.com – Jan 23, 2008
“Data presented in late 2007 from two large Phase 2b studies suggest that telaprevir dosed in combination with pegylated interferon and ribavirin may be able to meaningfully increase the proportion of treatment-naive genotype 1 HCV patients who achieve a sustained viral response and also cut the current treatment duration in half to 24 weeks” said John McHutchison M. Principal Investigator for the primary telaprevir Phase 3 pivotal study and Associate Director of Duke Clinical Research Institute. “Telaprevir is the most advanced protease inhibitor in development for hepatitis C and the initiation of Phase 3 clinical development for this investigational drug will begin the process of helping to further assess. CPYRIGHT 2008 Business Wire.

Myriad Genetics Inc. Expands Commercial and Clinical Infrastructure
Maketwire РMaketwire (Communiqu̩s de presse) РJan 23, 2008
as Director ofClinical Research in ncology and Andrew Beelen M. as Senior Directorof Clinical Research in Infectious Diseases. MBA will oversee professional educationpublications Phase 4 studies the CNS medical science liaison team andthe medical information functions at Myriad Pharmaceuticals Inc.

Healthcare Discoveries Inc. Central ECG Laboratory Services Partner…
Free with registration – Business Wire – AccessMyLibrary.com – Jan 23, 2008
Healthcare Discoveries Inc. Central ECG Laboratory Services Partner The Colorado Prevention Center Achieves Mortara Certified Partner Status. (23-JAN-08) Business Wire. Central ECG Laboratory Services Partner The Colorado Prevention Center Achieves Mortara Certified Partner Status. (HCD) and Colorado Prevention Center (CPC) who together provide innovative central electrocardiography (ECG) laboratory services announce that the CPC h.

Weight-loss operation can send diabetics into remission
Globe and Mail – Jan 23, 2008
Researchers found that 73 per cent of patients whose stomachs were shrunk with the simple surgical procedure were cured of Type 2 diabetes. By contrast only 13 per cent of diabetics who followed conventional therapy – dieting weight loss and medication – went into remission. John Dixon head of clinical research at the Centre for besity Research and Education at Monash University in Melbourne Australia and lead author of the paper stressed that obese patients saw their diabetes disappear when they lost significant amounts of weight.